Tuesday, March 31, 2020

Insulin Pump Market Plying for Significant Growth During 2017 – 2023



    The presence or lack of insulin, a hormone used for producing sugar in the body, can lead to type I or type II diabetes. Patients with hectic work schedules or living in urban regions require the need for special devices to ensure the continuous intake of insulin. Insulin pumps are computerized devices which have a similar functioning to human pancreas and deliver small doses of insulin during or after meal consumption. The global insulin pump market report by Market Research Future (MRFR) contains an analysis of trends as well as a list of drivers and opportunities.
    Market Outlook
    The global Insulin Pump Market is expected to touch a towering valuation by exhibiting 8.4% CAGR from 2017 to 2023 (forecast period). It can reach a valuation of USD 8,520.9 million by 2023. High prevalence of diabetes is one of the biggest market drivers. According to the International Diabetes Federation (IDF), nearly 642 million adults can be affected with diabetes by 2040. China and India are countries with the largest reported numbers for diabetes and have potential for the global market.
    Increasing focus on diabetes management is projected to push the sales of insulin pumps. Awareness initiatives by governments and vendor sponsored programs can influence patients and propel market demand. Popularity of insulin pump systems are driven by efforts by non-profit organizations such as the American Diabetes Association will be fruitful for the market. Other factors which can impact the market include sedentary lifestyles of patients, consumption of junk food, and adoption of insulin pumps. Furthermore, insulin pump accessories designed for women and kids can bode augment the market size.
    Segmentation Analysis
    The global insulin pump market is segmented by type, accessories, application, and end-user.
    By type, it is segmented into smart insulin pump, disposable insulin pump, and traditional insulin pump. The traditional insulin pump segment was the largest in 2016 and valued at USD 2,696.9 million. It can touch a value of USD 4,587.5 million by the end of the forecast period. On the other hand, disposable insulin pumps can continue on a winning streak due to being worn on the body and being controlled by an external body.
    By accessories, it is segmented into infusion set insertion devices, infusion sets, and insulin reservoirs.
    By application, it is segmented into type I diabetes and type II diabetes.
    By end-user, it is segmented into laboratories, home care, and hospitals & clinics. Hospitals & clinics had accounted for 45.2% share in 2016 with a valuation amounting to USD 2,188.2 million in 2016. The segment can accrue close to USD 3,908.8 million by 2023 due to management of inpatient care. Moreover, clinical trials of continuous subcutaneous insulin infusion (CSII) treatments can drive the segment growth as well. On the flip side, the home care segment is expected to exhibit 8.9% CAGR during the forecast period.

    Regional Analysis
    The Middle East & Africa (MEA), Europe, Asia Pacific, and North America are regions covered in the insulin pump market report.
    North America held the largest market share in 2016. It can continue to dominate the market till 2023 due to adoption of latest treatments, advanced medical facilities, and large healthcare expenditure allocated for minimizing the presence of diabetes. Rising rates of diabetes and obesity among patients can further the market demand in the region.
    On the other hand, the APAC region can display a stupendous growth rate due to high incidences of diabetes in Taiwan, Malaysia, Indonesia, China, and India. Availability of better medical facilities and a surge in disposable income levels can propel the demand for insulin pumps among patients.
    Competitive Outlook
    Notable players in the global insulin pump market include Abbott Laboratories, Medtronics, Sanofi, Insulet Corporation, F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Braun Melsungen AG, and others. Although new development of products is the primary strategy of these players, the exit of prominent names such as Johnson & Johnson leaves room for innovation and entry for new investors.
    Posted by at No comments:

    Cholesterol Test Market to Witness a Pronounce Growth During 2018 to 2025

    Global Cholesterol Test Market Research Report: Information by Product Type (Test Kits and Test Strips), Test Type (Total Cholesterol Test, High-Density Lipoprotein (HDL) Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol and Triglycerides/VLDL Cholesterol Test), Distribution Channel (Over the Counter and Prescription Based), End-User (Hospitals & Clinics, Homecare, Diagnostic Centers and others) and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa) - Forecast till 2025

    Market Highlights

    According to MRFR analysis, the Cholesterol Test Market is expected to register a CAGR of 7.4% during the forecast period of 2019 to 2025 and is expected to reach USD 2,465 Million by 2025.

    The growth of the global cholesterol test market is driven by various factors such as the increasing prevalence of cardiovascular diseases & obesity, government initiatives to improve the quality of clinical diagnostics. However, the lack of a skilled workforce is projected to hamper the growth of the global cholesterol test market.  

    According to recent studies, cardiovascular disease is the leading global cause of death, accounting for more than 17.6 million deaths per year in 2016, a number that is expected to grow to more than 23.6 million by 2030. The increasing incidences of obesity are driving the growth of the cholesterol test market. For instance, in 2016, 39% of adults aged 18 years and over (39% of men and 40% of women) were overweight. Globally, about 13% of the world's adult population was obese in 2016. The worldwide prevalence of obesity nearly tripled between 1975 and 2016,  

    Browse Full Report Details @ https://www.marketresearchfuture.com/reports/cholesterol-test-market-8738

    Regional Analysis

    The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the rising per capita healthcare expenditure. The cholesterol test market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. As per recent studies, most (55.4%) of the Canadian adult population categorized as overweight (34.2%) or obese (21.2%). Furthermore, the prevalence of obese classes I, II, and III will increase to 14.8%, 4.4% and 2.0%, respectively.

    The European cholesterol test market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. According to WHO, the obesity rate in Germany is 23.7% which means that Germany has one of the highest obesity rates in Europe, but is still behind the UK, which has a rate of 26.2 %.

    The cholesterol test market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of cardiovascular diseases and obesity, the market in Asia-Pacific is expected to be the fastest-growing. According to WHO, Obesity in China is a major health concern with overall rates of obesity between 5% and 6% for the country, but greater than 20% in some cities where fast food is popular. The cholesterol test market in the Middle East & Africa has been divided into the Middle East and Africa.


    Segmentation

    The Global Cholesterol Test Market has been segmented based on Product Type, Test Type, Distribution Channel, and End User. 

    The market, based on product type, has been divided into test kits and test strips. The test kits segment is likely to be the largest segment during the review period due to the growing awareness and adoption of preventive healthcare.

    The market, based on test type, has been divided into total cholesterol test, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides/VLDL cholesterol test. The total cholesterol test segment is likely to be the largest segment during the review period due to the growing importance of the test. A complete cholesterol test includes the calculation of four types of fats (lipids) in blood.

    The market, based on distribution channel, has been divided into over the counter and prescription-based. The prescription-based segment is likely to be the largest segment during the review period.  

    The global cholesterol test market has been segmented, based on end user, into hospitals & clinics, homecare, diagnostic centers, and others. The hospitals & clinics segment is expected to hold the majority share of the market owing to the rising in visits of patients in the hospitals and clinics.

    Key Players

    Some of the Key Players in the Global Cholesterol Test Market are Quest Diagnostics Incorporated, Cell Biolabs, Inc., Clinical Reference Laboratory, Inc., Laboratory Corporation of America Holdings, Randox Laboratories Ltd., Thermo Fisher Scientific, PTS DIAGNOSTICS, Alere Inc., F. Hoffmann-La Roche AG, and Eurofins Scientific.

    Posted by at No comments:

    Asthma Inhaler Device Market to Witness Exponential Growth by 2025

    Asthma Inhaler Device Market: Information by Type (Metered Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers), Mode of Operation (Manually Operated Inhaler Devices, Digitally-Operated Inhaler Devices), End User (Hospitals & Clinics, Homecare, Others) and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2025

    Market Highlights
    Asthma Inhaler Device Market is expected to register a CAGR of 6.42% during the forecast period with a market value of USD 19,677.54 Million till 2025. Inhaler devices have been proved to be the safest and most effective way to treat and control asthma and other respiratory diseases, as the inhaled medication reaches the lungs directly.

    Segment Analysis
    The Global Asthma Inhaler Device Market has been segmented by Type, Mode of Operation, and End User.
    The market, based on type, has been bifurcated into the metered-dose inhaler, dry powder inhaler, and soft mist inhaler. The metered-dose inhaler is further sub-segmented into standard pressurized metered-dose inhalers, breath-actuated pressurized metered-dose inhalers, and metered-dose inhaler with a spacer.
    Based on the mode of operation, the asthma inhaler device market has been segregated into manually operated inhaler devices and digitally operated inhaler devices.
    The global asthma inhaler device market, based on end-user, has been segmented into hospitals & clinics, home care, and others.

    Regional Analysis
    The Global Asthma Inhaler Device Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
    The Americas are likely to hold the largest share of the global asthma inhaler device market during the assessment period. The increase in the incidence of asthma, rising demand for metered-dose inhalers, adoption of smart inhalers by the population, and increasing demand for advanced technologies is expected to drive the market growth in the American region.
    The Europe market established substantial growth in the market due to the presence of major players such as GlaxoSmithKline PLC, AstraZeneca, and Boehringer Ingelheim, the rising adoption of respiratory inhalers by hospitals and patients in European countries and continuous efforts made by the European Academy of Allergy & Clinical Immunology to increase awareness about asthma.
    Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of rapidly developing economies such as China, India, and South Korea and the high prevalence of asthma.
    The asthma inhaler device market in the Middle East & Africa is expected to witness gradual growth owing to increasing cases of asthma and demand for better treatments in the Middle Eastern countries.


    Market Players
    MRFR recognizes the following companies as the key players in the Global Asthma Inhaler Device Market— GlaxoSmithKline plc (UK), Koninklijke Philips NV (Netherlands), AstraZeneca (UK), Cipla Inc. (India), Boehringer Ingelheim International GmbH (Germany), Beximco Pharmaceuticals Ltd (Bangladesh), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), Chiesi Farmaceutici SpA (Italy), and Medisol Lifescience Pvt. Ltd (India).
    Key Findings of the Study
    • The Global Asthma Inhaler Device Market is estimated to grow at USD 19,677.54 Million by 2025 at a CAGR of 6.42% during the assessment period
    • Americas accounted for the largest share of the global asthma inhaler device market due to the increasing incidence rate of asthma
    • Based on type, the metered dose inhalers segment accounted for the largest market share of 42.6% in 2018
    • Based on the mode of operation, the manually operated inhaler device segment accounted for the largest market share of 68.1% in 2018
    • On the basis of end-user, the hospitals & clinics segment accounted for the largest market share of 52.8% in 2018

    Posted by at No comments:

    Anxiety Disorder Treatment Market Size to Expand with Significant CAGR During 2019-2025

    Market Forecast
    Registering a CAGR of 5.4%, Anxiety Disorder Treatment Market Size is expected to reach USD 16.96 Million by 2025.
    People with anxiety disorders may feel anxious most of the time or for the brief, intense episodes, which may occur for no apparent reason. The main categories of anxiety disorders include phobia, panic disorder, generalized anxiety disorder, social anxiety disorder, selective mutism, and separation anxiety disorder.  
    Numerous established players dominate the market. The key players are involved in strategic initiatives to strengthen their market positions and expand their geographic presence in developing regions. Many players are investing in research activities to develop effective therapies to sustain in the market. For instance, Eli Lilly and Company launched Duloxetine and Forest Laboratories, Inc. launched Vilazodone, used for the treatment of generalized anxiety disorder.  

    Market Influencers
    Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major key players are positively influencing the market.  

    Regional Analysis
    On a regional basis, the Americas is anticipated to dominate the global Anxiety Disorder Treatment Market Size owing to the rising incidence of anxiety disorders in the region. For instance, generalized anxiety disorder affects 6.8 million adults, or 3.1% of the US population every year. Moreover, rising awareness campaigns regarding the anxiety disorders by the government and public organizations is driving the growth of the market in this region. For instance, the Anxiety and Depression Association of America (ADAA) started an initiative named BreaktheStigma. This campaign raises awareness regarding mental illness and end stigma and creates hope for those affected by mental illness.
    Europe is expected to hold the second-largest position in the global Anxiety Disorder Treatment Market Size owing to supportive government policies and raising public awareness about anxiety disorder treatments.
    Asia-Pacific is anticipated to be the fastest-growing region is due to the growing prevalence of psychological conditions such as anxiety disorders, rising interest of major key players in emerging markets, good quality healthcare infrastructure in this region. The Middle East & Africa has the least share of the global Anxiety Disorder Treatment Market Size. This is attributable to limited healthcare infrastructure and a lack of awareness about anxiety disorder treatments in this region.


    Segmentation
    The Global Anxiety Disorder Treatment Market Size has been segmented into drug class and end-user.
    By drug class, the market has been segmented into SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), TCAs (tricyclic antidepressants),      pregabalin, buspirone, benzodiazepines, and others.
    The global Anxiety Disorder Treatment Market Size, by end-user, has been segmented into hospitals, mental healthcare centers, asylums, and others.

    Key Players
    • Bristol-Myers Squibb Company     (US)
    • Eli Lilly and Company (US)
    • Johnson & Johnson (US)
    • AstraZeneca PLC (UK)
    • Sanofi-Aventis (France)
    • Forest Laboratories, Inc.     (US)
    • Pfizer, Inc. (US)
    • GlaxoSmithKline PLC (UK)
    • Lundbeck A/S (Denmark)
    • Merck & Co., Inc. (US)
    Posted by at No comments:

    ACE Inhibitors Market Forecast 2025 Research Forecast, Regional, Trends and Analysis

    ACE Inhibitors Market: Information by Drug (Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril and  others), Application (Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease and others), Dosage Form (Oral Tablets and Oral Solution), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites and Online Drug Stores) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

    Market Highlights
    According to MRFR analysis, ACE Inhibitors Market Forecast is expected to register a CAGR of 3.10% during the forecast period of 2019 to 2025 and is likely to be valued at USD 7682.8 Million in 2025.  
    The growth of the global ACE inhibitors market is determined by numerous factors such as rising adoption of ACE inhibitors for the treatment of cardiovascular complications and diabetic neuropathy, rising cases of cardiovascular disorders such as hypertension, and surge in demand for less expensive drugs. For instance, according to the data published by the World Health Organization (WHO) in 2017, the global prevalence rate of raised blood pressure in adults aged more than 18 was estimated to be 22.1% in 2017. However, side effects associated with the treatment and high costs of treatment are likely to hamper the growth of the global ACE inhibitors market during the forecast period. 

    Regional Analysis
    The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
    Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the growing prevalence of hypertension and cardiovascular disorders.       
    The European ACE inhibitors market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The ACE inhibitors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The presence of a huge population base, increasing awareness about cardiovascular disorders, and rising disposable income are the key factors responsible for the fastest growth of the market in Asia-Pacific. The ACE inhibitors market in the Middle East & Africa has been divided into the Middle East and Africa.

    Segmentation
    The Global ACE Inhibitors Market has been segmented based on Product, Application, Dosage Form, and Distribution Channel.
    The market, based on product, has been divided into lisinopril, ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others. The lisinopril is likely to hold the maximum market share in the global ACE inhibitors market owing to the growing adoption of lisinopril in the management of cardiovascular complications and diabetic neuropathy.
    The global ACE inhibitors market based on the application has been segregated into heart failure, hypertension, diabetes, heart attack, chronic kidney disease, and others. The hypertension segment is expected to hold a larger share of the market share owing to the rising cases of hypertension and the adoption of ACE inhibitors.
    The dosage form segment of the market is divided into oral tablets and oral solution. Capoten, Vasotec, Prinivil, Zestril, Lotensin, Monopril, and Altace are some well-known and widely used oral tablets.
    Based on distribution channel, the global ACE inhibitors market has been segmented into retail pharmacy, hospital pharmacy, e-commerce websites and online drug stores, and others. Retail pharmacy holds maximum market share during the forecast period.

    Access Report Details @ https://www.marketresearchfuture.com/reports/ace-inhibitors-market-8631

    Key Players
    Some of the Key Players in the Global ACE Inhibitors Market are Bristol-Myers Squibb Company (US), Par Pharmaceutical Companies, Inc. (US), UCB, Inc. (Belgium), Pfizer, Inc.(US), AbbVie Inc.(US), AstraZeneca (UK), Bausch Health Companies Inc.(Canada), Novartis AG (Switzerland), Merck & Co., Inc.(US), Teva Pharmaceutical Industries Ltd.(Israel), Silvergate Pharmaceuticals, Inc. (US), and others.
    Posted by at No comments:

    Uveitis Treatment Market Forecast : Overview by Types, Application, Key Players, Regional Outlook, Market Drivers & Restraints 2025

    Market Highlights
     
    According to MRFR analysis, Uveitis Treatment Market Forecast is expected to register a CAGR of 5.6% during the forecast period of 2019 to 2025 and was valued at USD 534.6 million in 2018.
    Uveitis is an inflammation that occurs in the uvea. It is found in people aged between 20 to 50. Based on the origin of inflammation, uveitis categories in major three types, namely, anterior uveitis, posterior uveitis, and intermediate uveitis.

    The growth of the global Uveitis Treatment Market Forecast is determined by numerous factors such as increasing research & development (R&D) expenditure, rising prevalence of uveitis and continuous product launches. However, side-effect related to corticosteroid drugs is projected to restrain the growth of the market during the forecast period.
     
    The global Uveitis Treatment Market Forecast is currently dominated by several market players. The key players are involved in expansion, product launches, and strategic collaborations to strengthen their market positions.

     Segmentation
    The global Uveitis Treatment Market Forecast has been segmented based on type, drug class, and end-user.
    The market, based on type, has been divided into anterior uveitis, intermediate uveitis, posterior uveitis, and others. The anterior uveitis is likely to hold maximum market share in the global Uveitis Treatment Market Forecast.
    The global Uveitis Treatment Market Forecast based on drug class has been segregated into corticosteroid drugs, anti-inflammatory drugs, immunosuppressive drugs, and others. The corticosteroids drugs segment is anticipated to hold the largest share in the market due to the rising preference in the treatment of uveitis.
    The end-user segments of the market are hospitals, specialty clinics, and others. The hospital’s segment is expected to hold the largest share of the market, as these are the primary locations where patients receive treatment.

     Key Players
    Some of the key players in the Global Uveitis Treatment Market Forecast are Allergan PLC, Novartis AG, Bausch Health, EyePoint Pharmaceuticals, Inc., AbbVie Inc., Horizon Therapeutics PLC, Mylan N.V., and Alimera Sciences.

     Browse Full Report Details @ https://www.marketresearchfuture.com/reports/uveitis-treatment-market-8457

     Regional Analysis
    The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
    The Americas are anticipated to hold the largest market share owing to the increasing prevalence of uveitis, the presence of a well-established healthcare sector, and high R&D expenditures. The Uveitis Treatment Market Forecast in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
    The European Uveitis Treatment Market Forecast has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Uveitis Treatment Market Forecast in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the presence of a large patient pool and expansion of healthcare facilities, the market in Asia-Pacific is expected to be the fastest-growing. The Uveitis Treatment Market Forecast in the Middle East & Africa has been divided into the Middle East and Africa.

     
     
    Posted by at No comments:

    Human Immunodeficiency Virus (HIV) Drugs Market Segments, Dynamics, Size, Supply & Demand, Current Trends and Forecast 2025



    Market Highlights
    According to MRFR analysis, Human Immunodeficiency Virus (HIV) Drugs Market is expected to register a CAGR of 5% during the forecast period of 2019 to 2025 and was valued at USD 24 million in 2018.
    HIV drugs aim to control the growth of the human immunodeficiency virus (HIV), improve the patient’s overall immune system, and reduce/stop the symptoms. The drugs used to treat HIV infection are antiretrovirals, which help reduce the viral load and fight the infection.
    The growth of the global HIV drug market is driven by the increasing prevalence of HIV infection, rising awareness of HIV treatment, and the launch of innovative drugs. However, stringent regulatory policies for drug approval and product recalls are expected to curb the growth of the global HIV drug market during the assessment period. The global Human Immunodeficiency Virus (HIV) Drugs Market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
    Segmentation
    The global HIV drug market has been segmented based on type and end-user. The market, based on type, has been divided into nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, integrase inhibitors, post-attachment inhibitors, and pharmacokinetic enhancers. The drugs in these different segments differ with respect to their mechanism of treating the HIV infection. The different approaches for treatment are, inhibiting HIV’s reverse transcriptase, preventing HIV maturation, and preventing the entry of the virus into the host cells, among others. The global Human Immunodeficiency Virus (HIV) Drugs Market has been segmented based on end-user, into hospitals & clinics, specialty centers, and others. The hospitals & clinics segment is expected to hold the largest market share due to an increasing number of hospitals.
    Key Players
    Some of the key players in the Global Human Immunodeficiency Virus (HIV) Drugs Market are Boehringer Ingelheim International, GmbH (Germany), Cipla Inc. (India), Merck & Co., Inc. (US), AbbVie Inc. (US), Bristol-Myers Squibb Company (US), Teva Pharmaceutical Industries Ltd (Israel), Gilead Sciences, Inc. (US), F.Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Aurobindo Pharma (India), Celltrion Healthcare Co., Ltd (South Korea), and ViiV Healthcare (UK).
    Regional Analysis  
    The market has been divided, by region, into Europe, the Americas, Asia-Pacific, and the Middle East & Africa. The Americas holds the largest market share. The Human Immunodeficiency Virus (HIV) Drugs Market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. Europe is expected to be the second-largest market owing to factors such as product launches by key players. The European Human Immunodeficiency Virus (HIV) Drugs Market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Human Immunodeficiency Virus (HIV) Drugs Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the growing awareness regarding the use of HIV drugs and the increasing incidence of HIV in the region, the market in Asia-Pacific is expected to be the fastest-growing. The Human Immunodeficiency Virus (HIV) Drugs Market in the Middle East & Africa has been divided into the Middle East and Africa and is expected to hold the least market share.
    Posted by at No comments:

    Anxiety Disorder Treatment Market Segmentation, Dynamics, Market Size, Supply & Demand, Competition & Companies, Drivers, Restraints and Technology 2025

    Market Forecast
    Registering a CAGR of 5.4%, Anxiety Disorder Treatment Market is expected to reach USD 16.96 Million by 2025.
    People with anxiety disorders may feel anxious most of the time or for the brief, intense episodes, which may occur for no apparent reason. The main categories of anxiety disorders include phobia, panic disorder, generalized anxiety disorder, social anxiety disorder, selective mutism, and separation anxiety disorder.  
    Numerous established players dominate the market. The key players are involved in strategic initiatives to strengthen their market positions and expand their geographic presence in developing regions. Many players are investing in research activities to develop effective therapies to sustain in the market. For instance, Eli Lilly and Company launched Duloxetine and Forest Laboratories, Inc. launched Vilazodone, used for the treatment of generalized anxiety disorder.  
    Market Influencers
    Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major key players are positively influencing the market.  
    Regional Analysis
    On a regional basis, the Americas is anticipated to dominate the global anxiety disorder treatment market owing to the rising incidence of anxiety disorders in the region. For instance, generalized anxiety disorder affects 6.8 million adults, or 3.1% of the US population every year. Moreover, rising awareness campaigns regarding the anxiety disorders by the government and public organizations is driving the growth of the market in this region. For instance, the Anxiety and Depression Association of America (ADAA) started an initiative named BreaktheStigma. This campaign raises awareness regarding mental illness and end stigma and creates hope for those affected by mental illness.
    Europe is expected to hold the second-largest position in the global anxiety disorder treatment market owing to supportive government policies and raising public awareness about anxiety disorder treatments.
    Asia-Pacific is anticipated to be the fastest-growing region is due to the growing prevalence of psychological conditions such as anxiety disorders, rising interest of major key players in emerging markets, good quality healthcare infrastructure in this region. The Middle East & Africa has the least share of the global anxiety disorder treatment market. This is attributable to limited healthcare infrastructure and a lack of awareness about anxiety disorder treatments in this region.
    Segmentation
    The Global Anxiety Disorder Treatment Market has been segmented into drug class and end-user.
    By drug class, the market has been segmented into SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), TCAs (tricyclic antidepressants),      pregabalin, buspirone, benzodiazepines, and others.
    The global anxiety disorder treatment market, by end-user, has been segmented into hospitals, mental healthcare centers, asylums, and others.
    Key Players
    • Bristol-Myers Squibb Company (US)
    • Eli Lilly and Company (US)
    • Johnson & Johnson (US)
    • AstraZeneca PLC (UK)
    • Sanofi-Aventis (France)
    • Forest Laboratories, Inc. (US)
    • Pfizer, Inc. (US)
    • GlaxoSmithKline PLC (UK)
    • Lundbeck A/S (Denmark)
    • Merck & Co., Inc. (US)
    Posted by at No comments:

    Antiemetics Market Covering Competitive Scenario & Market Dynamics throughout 2025



    Market Highlights
    According to MRFR analysis, Antiemetics Market is expected to register a CAGR of 6.6% during the forecast period of 2019 to 2025 and account for USD 6.7 Billion in 2025.
    The Global Antiemetics Market is expected to grow at a steady pace. There are numerous antiemetics agents available for the treatment of nausea and vomiting, including; dopamine antagonists, anticholinergics, antihistamines, serotonin antagonists, and others. The key players manufacturing these products include GSK, Merck, and Pfizer Inc. As these players generate their maximum revenue from the Americas for the market, the region accounted for significant share across the globe.
    The market is expected to grow at a steady growth rate. The significant factors influencing the growth of the market include increasing investment in the pharmaceutical industry, increasing the number of postoperative procedures, pregnancy-induced nausea, and acute gastroenteritis, further influencing the growth of the market. Moreover, the rising demand for novel therapeutics and the increasing prevalence of postoperative nausea and vomiting (PONV) is responsible for positive market growth.  
    Segmentation
    The Global Antiemetics Market has been segmented into agents, drug type, application, and distribution channel.
    By agents, the market has been segmented into dopamine antagonists, anticholinergics, antihistamines, serotonin antagonists, cannabinoids, and others. Furthermore, dopamine antagonists is segmented into phenothiazines (chlorpromazine, prochlorperazine), butyrophenones (droperidol, domperidone ), and benzamides. Moreover, serotonin antagonists is further divided into ondansetron, granisetron. The others segment includes dexamethasone and propofol. Dopamine accounted for the largest market share majorly due to FDA approval for the maximum number of application
    By drug type, the market is segmented into prescribed and OTC. Prescribed drugs accounted for the large share by drugs type due to the high cost of the drugs when compared to OTC and also are most prescribed by the professionals.
    Based on application, the market is segmented into chemotherapy, motion sickness, stomach flu, pregnancy, postoperative surgery, and others. Postoperative surgery accounted for the largest market share on the basis of attributing to an increasing number of surgery procedures and mandatory postoperative procedures for the same.
    The global antiemetics market, by distribution channel, has been a retail pharmacy, hospital pharmacy, online. On the basis of distribution channel, retail pharmacies accounted for the largest share due to the presence of a large number of retail pharmacies across the globe.
    Key Players
    Some of the key players in the Global Antiemetics Market are GSK (UK), Merck (US), Sanofi-Aventis (France), Pfizer Inc. (US), Mylan (US), Eli Lilly and Company (US), Johnson & Johnson (US), Baxter International (US), Dr. Reddy's Laboratories Inc. (India) and others.
    Regional Analysis
    On a regional basis, the Americas are anticipated to dominate the global antiemetics market owing to the growing clinical research & development budgets by both public and private organizations in the pharmaceutical industry, increasing demand for novel therapeutics and the abundant presence of significant manufacturer in the region. Additionally, rising postoperative procedures is expected to influence the growth of the market. According to a study, it is found that PONV occurs in nearly 30% of the general surgical population and up to 70% to 80% of high-risk surgical patients. Europe is expected to account for the second-largest market in the global antiemetics market owing to well-developed research infrastructure, increasing healthcare awareness in the region, and high expenditure in pharmaceutical research.
    Moreover, rising healthcare expenditure is boosting the market in this region. Asia-Pacific is expected to be the fastest-growing region due to the growing interest of major key players in entering emerging markets, increasing development in the pharmaceutical industry in this region. Moreover, increasing the adoption of chemotherapy for the treatment of cancer expected to influence the growth of the market. The Middle East & Africa is expected to account for the least share of the global antiemetics market. Moreover, the significant market share of the region is expected to be held by the Middle East region owing to the increasing investment by major manufacturers and changing healthcare reforms.
    Posted by at No comments:

    Bronchodilators Market Analysis to Register Steady Growth During 2017 to 2025



    Market Highlights
    According to MRFR analysis, Bronchodilators Market Analysis is expected to register a CAGR of 5.30% during the forecast period of 2019 to 2025 and is expected to reach USD 2,484 Million by 2025.
    Bronchodilators are medications that make breathing easier by opening the airways of the lung by relaxing bronchial muscles. They are used to treat various respiratory problems such as asthma, COPD, and other allergic reactions that cause breathing problems.
    The growth of the global Bronchodilators Market Analysis is driven by various factors such as increase in prevalence of pulmonary disorders, increasing geriatric population and increasing mergers and acquisitions by prominent players in the market. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of the bronchodilators are projected to hamper the growth of the global Bronchodilators Market Analysis.
    The global Bronchodilators Market Analysis is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in April 2019, Cipla Technologies entered into agreement with Pulmatrix Inc. to co-develop a formulation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
    Segmentation
    The global Bronchodilators Market Analysis has been segmented based on drug type, disease, mode of action, and route of administration.
    The market, based on drug type, has been divided into adrenergic drugs, anticholinergics, a phosphodiesterase inhibitor, and combination drugs.
    The adrenergic segment is likely to be the largest during the review period as they are the most potent bronchodilators approved for clinical use in asthma and obstructive lung disease. The combination drugs segment is predicted to be the fastest-growing segment. These combination drugs are used if COPD and asthma are not controlled with monotherapy. These combinations involving two long-acting bronchodilators with differing modes of action.
    The global Bronchodilators Market Analysis has been segmented, on the basis of disease, into asthma, COPD, and others. The asthma segment is expected to hold the majority share of the market, owing to the rise in patients affected with asthma. The COPD segment is expected to be the fastest-growing as bronchodilators are primary treatment for chronic obstructive pulmonary disease (COPD) as they help to alleviate bronchial obstruction and airflow limitation.
    In terms of mode of action, the global Bronchodilators Market Analysis has been segmented into short-acting bronchodilators and long-acting bronchodilators. Short-acting bronchodilators are expected to be the largest segment, owing to its ability to provide quick relief from sudden, unexpected attacks of breathlessness.
    The route of administration of the market is oral and parenteral. The oral route of administration segment is expected to hold the largest share of the market due to the advantages such as ease and simplicity of administration along with control of delivered dose.
    Key Players
    Some of the key players in the Global Bronchodilators Market Analysis are GlaxoSmithKline (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany), AstraZeneca plc (UK), F. Hoffmann LA-Roche AG (Switzerland), Teva Pharmaceutical (Israel) and Pfizer Inc. (US) among others.
    Regional Analysis
    The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are expected to be the largest market owing to the rising per capita healthcare expenditure. The Bronchodilators Market Analysis in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European Bronchodilators Market Analysis has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Bronchodilators Market Analysis in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of respiratory disorders and the increasing pool of patient population, the market in Asia-Pacific is expected to be the fastest-growing. The Bronchodilators Market Analysis in the Middle East & Africa has been divided into the Middle East and Africa.
    Posted by at No comments:
    Subscribe to: Posts (Atom)